AKTX — Akari Therapeutics Plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1541157 ·
Last close
$8.70
Market Cap
$15.23M
52W High
$29.32
52W Low
$3.02
ADV30
83,116
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,628,000 | -14,455,000 | 33,889,000 | 2,768,000 | 19,509,000 |
| Dec 2025 | 0 | — | -3,227,000 | -5,298,000 | 47,892,000 | 5,203,000 | 19,564,000 |
| Sep 2025 | 0 | — | -2,224,000 | -6,400,000 | 45,376,000 | 2,484,000 | 22,689,000 |
| Jun 2025 | 0 | — | -3,119,000 | -1,895,000 | 50,911,000 | 2,711,000 | 25,306,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,906,000
Investing CF
—
Financing CF
$11,091,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,005,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,955,000
Pretax Income TTM
$-29,910,000
Interest Exp TTM
$955,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,095,000 | -17,298,000 | 47,892,000 | 19,564,000 | — | -10,568,000 |
| Dec 2024 | 0 | -16,647,000 | -19,791,000 | 50,562,000 | 28,333,000 | — | -12,552,000 |
| Dec 2023 | 0 | -16,806,000 | -10,008,000 | 4,355,000 | 4,584,000 | — | -16,432,000 |
| Dec 2022 | 0 | -23,088,000 | -17,748,000 | 13,832,000 | 12,041,000 | — | -21,504,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-14.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LSTA | LISATA THERAPEUTICS, INC. | $15.21M | $1.67 | — |
| KTTA | Pasithea Therapeutics Corp. | $15.20M | $0.46 | — |
| CYCN | Cyclerion Therapeutics, Inc. | $15.16M | $3.50 | — |
| INTI | Inhibitor Therapeutics, Inc. | $15.01M | $0.09 | — |
| SCNX | Scienture Holdings, Inc. | $15.00M | $0.37 | — |
News headlines (Yahoo Finance, 1h cache)
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
2026-07-24 15:06 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-07-22 15:10 · Yahoo
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
2026-07-22 12:40 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-07-21 15:10 · Yahoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 11:05 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
2026-07-20 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading
2026-07-08 15:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
2026-07-07 15:07 · Yahoo
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
2026-07-07 12:55 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
2026-07-06 15:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.